Features

Innovation is central to the bio/pharma industry, so what have been the key developments in 2025? Which companies and their innovation stand out? DCAT Value Chain Insights takes an inside look.

What has been the impact of US tariffs thus far on global trade, including on pharmaceuticals and pharmaceutical ingredients? Plus, Switzerland is the latest country to strike a new tariff deal.

Driven by oncology indications, strong growth is on tap for the global market for antibody drug conjugates (ADCs) and the ADC contract manufacturing market. DCAT Value Chain Insights takes an inside look.

Small-molecule and chemically synthesized drugs continue to the dominate new drug approvals by FDA, with about 75% of such approvals in 2025 coming from small-to-medium-sized pharma companies. 

The US Supreme Court heard oral arguments in cases involving the legality of reciprocal tariffs, country-by-country tariffs imposed through a series of trade deals and executive actions. Is tariff relief a possibility or not?

Which biologics have received approval by FDA’s Center for Drug Evaluation and Research thus far in 2025, and how are they positioned in the market? What other market contenders loom in the industry’s pipeline?

Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?

Partnering deals and MA& among the large bio/pharma companies and smaller companies not only reflect strategic decisions by the bio/pharma majors to build their product portfolios, but also put these smaller companies on the industry map. Which companies are making the mark in 2025?

Roche released its earnings for the first nine months of 2025, which saw its pharmaceutical revenues increase by 9% at constant exchange rates. Its top five growth drivers – Phesgo, Xolair, Hemlibra, Vabysmo and Ocrevus – achieved total sales of nearly $20 billion. Will momentum continue?

mRNA technology was lifted into commercial success during the pandemic, with two major mRNA vaccines, Pfizer’s/BioNTech’s Comirnaty and Moderna’s Spikevax. With that market closing, where does the mRNA pipeline stand? Is oncology the next wave?